Prosigna®

## Breast Cancer Assay

2nd generation test
that can help physicians more comprehensively **inform treatment decisions.**

More Accurate Prognostic Score

Intrinsic Molecular Subtype Identified

Clinicopathological Factors Integrated

CE-IVD marked & guideline recommended

veracyte®

Prosigna® helps to accurately distinguish high-, intermediate-, and low-risk groups[1] when compared to the 1st generation assays and can better inform treatment decisions.[1]

2nd GENERATION ASSAY Prosigna®

- 50 genes
- Gene expression + clinical factors (age, node status, tumor size, histologic grade)
- Results can be available in as little as 24 hours

10-YEAR PROGNOSIS

1st GENERATION ASSAY

- 21 genes
- Clinical and pathological factors not included in risk calculation
- Samples need to be sent out

5 to 9-YEAR PROGNOSIS

	Number of Women	Number of DR	10-year DR Risk (%)
Prosigna ROR low and Oncotype Dx RS low	104	2	2.1%
Prosigna ROR low, but Oncotype Dx RS intermediate or high	**261**	**7**	**2.9%**
Prosigna ROR intermediate or high, but Oncotype Dx RS low	**62**	**10**	**18.2%**
Prosigna ROR high and Oncotype Dx RS high	55	14	19.5%

With 1st generation assays, nearly 20% of patients can be wrongly assigned to a low-risk group and not receive life-saving chemotherapy.[1]

Clinically Validated Algorithm Generates a Prosigna® Score Unique for Each Patient.

Prosigna® measures the expression of 50 different genes to identify subtype and report a Risk of Recurrence Score (ROR), which is used to assign the patient to a predefined risk group. These results presented in the Patient Report are derived from a proprietary algorithm based on the PAM50 gene signature, intrinsic subtype, and clinical variables including tumor size and nodal status.


Patient expression profile

Prosigna centroids

LumB LumA Basal-like HER2-enriched

+

Nodal Status

Node 0
Node 1-3

Gross Tumour size

<2cm
≥2cm

+

Prosigna® Score =

aR_{LumA} +

bR_{LumB} +

cR_{Her2e} +

dR_{Basal} +

} Pearson's correlation to centroids

eP +

fT

} Proliferation score & Gross tumour size

=

Patient Report

How does the Prosigna® Assay work?

1

Extract RNA from FFPE* tumour sample

with the Veracyte
FFPE RNA Extraction Kit

2

Test RNA using Prosigna® Assay

on the nCounter Analysis System in your local lab in as little as 24 hours

3

Capture expression profile

of patient's tumour for tailored, more accurate and better informed treatment decisions


4

Patient Report

to enable fast and precise treatment decisions:

- **Intrinsic Molecular Subtypes identified**
- **Risk of Recurence (ROR)** within 10 years
- **Clinicopathological factors** like tumour size and nodal status incorporated in the score

**FFPE*: Formalin Fixed Paraffin Embedded Tissue.

Prosigna®

Breast Cancer Assay

More **comprehensive information about your patient's tumour** helps provide fast, precise and tailored **treatment decisions.**

Provides more accurate prognosis **to help improve breast cancer treatment and outcomes**[1].

Combines **tumour gene expression and clinicopathological factors** in a single 10-year Risk of distant Recurrence (ROR) score[2,3] for informed treatment decisions.

The only breast cancer prognostic test identifying the **four PAM50 intrinsic molecular subtypes for** tailored treatments.

Easy access to local testing with **faster turnaround times. Results can be available in as little as 24 hours.**

References:
1. Sestak I, Buus R, Cuzick J, et al. JAMA Oncol. 2018; 4(4):545–553. **2**. Kos et al. Breast Cancer Res, 2014, 16:103. **3**. Alexandre et al. Cancer Manag Res, 2019; 11: 10353–10373.

veracyte®